Combo Provides ‘Broad Benefit’ Across NHL Subtypes
The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progressi...
Quality of Life on Cancer Drugs ― Still Largely a Mystery
Just a 20-minute walk from the Leiden University M...